Fractionated total body irradiation and high-dose etoposide as a preparatory regimen for bone marrow transplantation for 99 patients with acute leukemia in first complete remission

Autor: DS Snyder, NJ Chao, MD Amylon, J Taguchi, GD Long, RS Negrin, AP Nademanee, MR O'Donnell, GM Schmidt, AS Stein

Publikováno v: Blood. 82(9)

Ninety-nine consecutive patients with acute leukemia in first complete remission under age 50 (median age 27 years; age range 1 to 47 years) with a histocompatible sibling donor were treated with fractionated total body irradiation (1,320 cGy) and hi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23f40fd13814b30486aa341dcf89246a
https://pubmed.ncbi.nlm.nih.gov/8219241

Dynamic assessment of quality of life after autologous bone marrow transplantation

Autor: NJ Chao, DK Tierney, JR Bloom, GD Long, TA Barr, BA Stallbaum, RM Wong, RS Negrin, SJ Horning, KG Blume

Publikováno v: Blood. 80(3)

To determine the quality of life in adult patients after autologous bone marrow transplantation (BMT), we administered a questionnaire to a cohort of patients seen at a single referral-based center. The sample included adults 18 years and older durin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::470add4c279572e40dec4501021a2c33
https://pubmed.ncbi.nlm.nih.gov/1638031

Financial Toxicity and Quality of Life in Patients Undergoing Stem-Cell Transplant Evaluation: A Single-Center Analysis.

Autor: Hussaini SMQ; O'Neal Comprehensive Cancer, University of Alabama at Birmingham, Birmingham, AL.; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, MD.; Department of Medicine, Duke University School of Medicine, Durham, NC., Ren Y; Duke Cancer Institute Biostatistics Shared Resource, Durham, NC., Racioppi A; Department of Medicine, Duke University School of Medicine, Durham, NC., Lew MV; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Bohannon L; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Johnson E; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Li Y; Duke Cancer Institute Biostatistics Shared Resource, Durham, NC., Thompson JC; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Henshall B; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Darby M; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Choi T; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Lopez RD; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Sarantopoulos S; Duke Cancer Institute Biostatistics Shared Resource, Durham, NC., Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Long GD; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Horwitz ME; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Chao NJ; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC., Zafar SY; Department of Medicine, Duke University School of Medicine, Durham, NC., Sung AD; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC.

Publikováno v: JCO oncology practice [JCO Oncol Pract] 2024 Mar; Vol. 20 (3), pp. 351-360. Date of Electronic Publication: 2023 Dec 21.

Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years.

Autor: Lew MV; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Ren Y; Duke Cancer Institute Biostatistics Shared Resources, Durham, North Carolina., Lowder YP; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Siamakpour-Reihani S; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Ramalingam S; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Romero KM; Duke University School of Medicine, Durham, North Carolina., Thompson JC; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Bohannon LM; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., McIntyre J; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Tang H; Duke University School of Medicine, Durham, North Carolina., Van Opstal J; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina; Faculty of Medicine, KU Leuven, Leuven, Belgium., Johnson E; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Cohen HJ; Claude D. Pepper Older Americans Independence Center, Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina., Bartlett DB; Claude D. Pepper Older Americans Independence Center, Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina; School of Biosciences and Medicine, University of Surrey, Surrey, United Kingdom., Pastva AM; Claude D. Pepper Older Americans Independence Center, Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina; Department of Orthopedic Surgery, Division of Physical Therapy, Duke University Medical Center, Durham, North Carolina., Morey M; Claude D. Pepper Older Americans Independence Center, Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina; Geriatric Research, Education and Clinical Center, Durham VA Healthcare System, Durham, North Carolina., Hall KS; Claude D. Pepper Older Americans Independence Center, Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina; Geriatric Research, Education and Clinical Center, Durham VA Healthcare System, Durham, North Carolina., Smith P; Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina., Peters KB; Departments of Neurology and Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina., Somers TJ; Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina., Kelleher S; Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina., Smith SK; School of Nursing, Duke University Medical Center, Durham, North Carolina., Wischmeyer PE; Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina., Lin PH; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina., Wood WA; Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Thorpe G; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Minor K; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Wiggins K; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Hennig T; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Helms T; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Welch R; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Matthews B; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Liu J; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Burleson J; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Aberant T; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Engemann AK; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Henshall B; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Darby M; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Proch C; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Dellascio M; Duke Health Department of Physical Therapy and Occupational Therapy, Durham, North Carolina., Pittman A; Duke Health Department of Physical Therapy and Occupational Therapy, Durham, North Carolina., Suminguit J; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Choi T; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina., Long GD; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina., Lopez RD; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Sarantopoulos S; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Horwitz ME; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina., Chao NJ; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, North Carolina., Sung AD; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina; Claude D. Pepper Older Americans Independence Center, Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina. Electronic address: anthony.sung@duke.edu.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2022 Aug; Vol. 28 (8), pp. 498.e1-498.e9. Date of Electronic Publication: 2022 May 17.

Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation.

Autor: Islam P; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Tang H; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Jin H; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Cao F; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Bohannon LM; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Ren Y; Duke Cancer Institute, Biostatistics Shared Resources, Duke University, Durham, North Carolina., Chao NJ; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Choi T; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Horwitz ME; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Long GD; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Lopez RD; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Rizzieri DA; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Sarantopoulos S; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina., Sung AD; Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina. Electronic address: anthony.sung@duke.edu.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2021 Sep; Vol. 27 (9), pp. 784.e1-784.e7. Date of Electronic Publication: 2021 Jun 17.